FASTII international multicenter trial confirms high diagnostic accuracy of CAAS vFFR
Maastricht, 19th May 2021. Pie Medical Imaging (“PMI”), a global leader in cardiac imaging, today announced the conclusion of the FASTII trial and presentation of the results as a late breaking clinical trial at EuroPCR 2021.
CAAS vFFR is an innovative technology allowing the non-invasive physiological assessment of coronary lesions. It calculates a pressure drop and vFFR value using angiography images only, without the need for invasive coronary artery instrumentation and/or adenosine.